SG Americas Securities LLC trimmed its stake in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 82.6% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,938 shares of the company's stock after selling 42,562 shares during the period. SG Americas Securities LLC's holdings in Cellebrite DI were worth $151,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. grew its holdings in Cellebrite DI by 59.6% during the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company's stock worth $33,000 after acquiring an additional 1,017 shares during the period. Public Employees Retirement Association of Colorado acquired a new stake in Cellebrite DI during the 2nd quarter worth about $71,000. nVerses Capital LLC bought a new position in shares of Cellebrite DI during the 2nd quarter worth about $103,000. TD Asset Management Inc bought a new position in shares of Cellebrite DI during the 2nd quarter worth about $121,000. Finally, Magnetar Financial LLC bought a new position in shares of Cellebrite DI during the 2nd quarter worth about $143,000. 45.88% of the stock is currently owned by institutional investors and hedge funds.
Cellebrite DI Trading Up 2.0 %
NASDAQ CLBT traded up $0.35 during trading hours on Friday, hitting $18.29. The company's stock had a trading volume of 1,084,946 shares, compared to its average volume of 1,126,890. Cellebrite DI Ltd. has a 52 week low of $6.36 and a 52 week high of $18.75. The company has a market capitalization of $3.77 billion, a PE ratio of -33.85, a price-to-earnings-growth ratio of 2.48 and a beta of 1.52. The company's 50-day simple moving average is $17.24 and its two-hundred day simple moving average is $13.68.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its quarterly earnings data on Thursday, August 15th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.08 by $0.02. The firm had revenue of $95.70 million during the quarter, compared to analyst estimates of $91.94 million. Cellebrite DI had a negative net margin of 28.51% and a positive return on equity of 5,902.06%. The company's revenue for the quarter was up 24.8% on a year-over-year basis. During the same quarter last year, the business posted $0.05 EPS. Research analysts anticipate that Cellebrite DI Ltd. will post 0.31 EPS for the current fiscal year.
Analyst Ratings Changes
A number of research firms have recently issued reports on CLBT. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Cellebrite DI from $15.00 to $18.00 and gave the stock a "buy" rating in a research report on Friday, August 16th. TD Cowen increased their price objective on shares of Cellebrite DI from $20.00 to $23.00 and gave the stock a "buy" rating in a research report on Monday, September 23rd. Craig Hallum increased their price objective on shares of Cellebrite DI from $20.00 to $23.00 and gave the stock a "buy" rating in a research report on Wednesday, September 25th. Bank of America increased their price objective on shares of Cellebrite DI from $13.00 to $17.00 and gave the stock a "buy" rating in a research report on Friday, August 16th. Finally, Lake Street Capital increased their price objective on shares of Cellebrite DI from $13.50 to $17.00 and gave the stock a "buy" rating in a research report on Friday, August 16th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $18.57.
Check Out Our Latest Analysis on Cellebrite DI
Cellebrite DI Company Profile
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Stories
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.